COVID-19 Vaccine Candidate Found 94.5% Effective

Massachusetts based Moderna, Inc. announced that the independent, NIH-appointed Data Safety Monitoring Board for the Phase 3 study of the mRNA-1273 vaccine candidate informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.

Moderna stated it intends to submit for an Emergency Use Authorization with the U.S. FDA and plans to submit similar applications to global regulatory agencies.

By the end of 2020, the Company expects to have approximately 20 million doses of mRNA-1273 ready to ship in the USA and remains on track to manufacture 500 million to 1 billion vaccine doses globally in 2021.